HI
APGE icon

HBK Investments’s Apogee Therapeutics APGE Stock Holding History

HBK Investments’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378M Buy
+2,850,000
New +$257M 3.7% 9

Other funds holding APGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments's APGE Position: Q2 2026 in Review

HBK Investments opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 2,850,000 shares worth $378M. The stake represents 3.7% of the portfolio and ranks #9 among its holdings.

258 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • HBK Investments held 2,850,000 shares of Apogee Therapeutics worth $378M as of Q2 2026.
  • Apogee Therapeutics was a new HBK Investments position in Q2 2026.
  • Apogee Therapeutics made up 3.7% of HBK Investments's portfolio in Q2 2026, its #9 holding.
  • 258 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on HBK Investments's 13F filing for Q2 2026, filed 14 Aug 2026.